Core Insights - Lifecore Biomedical, Inc. will participate in multiple investor conferences and industry events in March 2025, showcasing its commitment to engaging with investors and industry stakeholders [1][2]. Group 1: Upcoming Events - Lifecore will present at the TD Cowen 45th Annual Health Care Conference on March 4, 2025, where CEO Paul Josephs will deliver a corporate presentation [1]. - The company will also participate in the KeyBanc Capital Markets Healthcare Forum on March 19, 2025, featuring a fireside chat with CEO Paul Josephs [2]. - Additionally, Lifecore will attend DCAT Week 2025 from March 17-20, 2025, engaging in meetings with current and prospective customers [2]. Group 2: Company Overview - Lifecore Biomedical is a fully integrated contract development and manufacturing organization (CDMO) specializing in the development, fill, and finish of sterile injectable pharmaceutical products [3]. - The company has over 40 years of expertise in manufacturing premium, injectable-grade hyaluronic acid, serving global and emerging biopharmaceutical and biotechnology companies [3].

Company Participation - Lifecore Biomedical, Inc. will participate in the 2025 BIO CEO & Investor Conference scheduled for February 10-11, 2025, in New York, NY [1] - The company's management, including CEO Paul Josephs and CFO Ryan Lake, will engage in 1-on-1 meetings during the conference [1] Company Overview - Lifecore Biomedical is a fully integrated contract development and manufacturing organization (CDMO) specializing in the development, fill, and finish of sterile injectable pharmaceutical products [2] - The company has over 40 years of expertise in manufacturing premium, injectable-grade hyaluronic acid and serves global and emerging biopharmaceutical and biotechnology companies across multiple therapeutic categories [2]

Core Points - Lifecore Biomedical, Inc. plans to hold a special meeting on April 10, 2025, to seek stockholder approval for a proposal to remove the Convertible Preferred Stock Exchange Cap, allowing for potential conversion of Series A Preferred Stock beyond the current limit of 19.99% of outstanding Common Stock [1][2] - The current maximum number of shares of Common Stock that can be converted from the Convertible Preferred Stock is 6,056,284 shares, and no holders have yet elected to convert their shares [2] - The board of directors has set February 18, 2025, as the record date for stockholders entitled to vote at the special meeting [3] Proposal Details - The proposal aims to eliminate the limitation on the conversion of Convertible Preferred Stock, which is currently capped at 19.99% of the outstanding Common Stock prior to issuance [2] - The meeting is specifically to accommodate the terms of the Convertible Preferred Stock Securities Purchase Agreement dated January 9, 2023, and Lifecore has no current plans to raise additional equity capital [2] Proxy Statement and Participation - Lifecore intends to file a preliminary proxy statement with the SEC regarding the special meeting, followed by a definitive proxy statement after SEC clearance [4] - Stockholders will receive further details on how to participate and vote at the special meeting through the definitive proxy statement [4] Company Overview - Lifecore Biomedical is a fully integrated contract development and manufacturing organization (CDMO) specializing in the development and manufacturing of sterile injectable pharmaceutical products, including injectable-grade hyaluronic acid [5]

Core Viewpoint - Lifecore Biomedical is strategically positioned for mid-term and long-term growth, supported by its current capacity to generate up to $300 million in annual revenue through the recent installation of a high-speed 5-head filler and the sale of excess equipment [1][2]. Group 1: Financial Transactions - Lifecore has entered into a sales agreement for a high-speed, multi-purpose 10-head isolator filler, receiving an aggregate purchase price of $17 million, with $7 million received at closing and the remainder to be paid in three tranches over the next 18 months [1][2]. - The sale of the 10-head filler is viewed as a compelling opportunity to monetize unused equipment and enhance the company's financial position [2]. Group 2: Operational Capacity - The installation of the new high-speed, multi-purpose 5-head isolator filler has doubled Lifecore's available capacity, allowing the company to better serve existing and future customers [2]. - The 5-head filler is GMP-ready, and the company is currently engaging in discussions with customers to leverage its speed and aseptic isolation capabilities [2]. Group 3: Company Overview - Lifecore Biomedical is a fully integrated contract development and manufacturing organization (CDMO) specializing in the development, fill, and finish of sterile injectable pharmaceutical products, including complex formulations [3]. - The company has over 40 years of expertise in manufacturing premium, injectable-grade hyaluronic acid and partners with global and emerging biopharmaceutical and biotechnology companies [3].

CHASKA, Minn., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that the company will participate at the 43rd Annual J.P. Morgan Healthcare Conference. The conference will take place January 13-16, 2025, in San Francisco, California. Details regarding Lifecore’s participation are as follows: 43rd Annual J.P. Morgan Healthcare ConferenceDetails: Lifecore management, includi ...

Lifecore Biomedical, Inc. (NASDAQ:LFCR) Q2 2025 Earnings Conference Call January 2, 2025 4:00 PM ET Company Participants Stephanie Diaz - Manager, IR Paul Josephs - President & CEO Ryan Lake - CFO Conference Call Participants Matt Hewitt - Craig-Hallum Capital Group Jacob Johnson - Stephens Michael Petusky - Barrington Research Operator Good afternoon, and thank you for joining Lifecore's Financial 2025 Second Quarter Earnings Call. During the call, all participants will be in a listen-only mode. Now I woul ...

Revenue Growth - Revenues increased by $2.0 million in HA manufacturing primarily due to higher sales volume from the largest customer[184] - CDMO revenues increased by $0.6 million, driven by $3.3 million higher sales volume from the largest customer, partially offset by $2.6 million reduction due to a customer working down inventory levels[184] Expenses and Costs - R&D expenses for the three months ended November 24, 2024 were $1.924 million, a decrease of $0.174 million (8%) compared to the prior period[177] - SG&A expenses increased by $1.777 million (19%) primarily due to $1.8 million increase in non-cash stock-based compensation expense[178] - Interest expense, net increased by $1.392 million (34%) to $5.465 million for the three months ended November 24, 2024[179] - Other expense, net decreased by $0.663 million (69%) primarily due to the end of accumulation of monetary penalties to preferred stockholders[181] Financial Liabilities and Derivatives - Change in fair value of debt derivative liability, related party decreased by $19.5 million (94%) to $1.2 million[179] Legal and Compliance - The company intends to vigorously defend against claims filed by 22NW Fund, L.P. regarding alleged material misrepresentations and breaches of the Securities Purchase Agreement[191] - The company is committed to remediating control deficiencies by adding qualified personnel, enhancing controls, and implementing a SOX Steering Committee[295][296][300] Business Relationships - The company has established long-term relationships with global and emerging biopharmaceutical and biotechnology companies across multiple therapeutic categories[169]

Core Insights - Lifecore Biomedical, Inc. reported revenues of $32.6 million for Q2 Fiscal 2025, reflecting an 8% increase compared to $30.2 million in the same period last year [8][12] - The company signed multiple development agreements with new customers, enhancing its early-stage development pipeline [3][2] - Lifecore strengthened its balance sheet by raising approximately $24.3 million through equity financing and restructuring its credit facility with BMO [5][6] Financial Performance - Revenues for the six months ended November 24, 2024, were $57.3 million, a 5% increase from $54.7 million in the prior year [13] - Gross profit for Q2 was $11.1 million, up from $10.0 million year-over-year, driven by increased CDMO gross profit [9] - The company recorded a net loss of $6.6 million for Q2, compared to a net income of $14.2 million in the same period last year [12] Operational Developments - Lifecore successfully installed and qualified a high-speed, multi-purpose 5-head isolator filler, doubling its capacity and creating a potential revenue-generating capacity of up to $300 million annually [4] - The company appointed several key executives to support its growth strategy, including a new CFO and senior vice president of human resources [7] Business Development - Lifecore signed two new project agreements with Nirsum Laboratories, focusing on CDMO services for clinical development [3] - The business development team achieved significant milestones during the quarter, contributing to the overall growth strategy [2] Balance Sheet and Financing - The company completed a $24.3 million private placement of shares, enhancing its financial position [5] - Lifecore amended its revolving credit facility with BMO, resulting in a three-year extension and reduced interest rates [6]

Core Insights - Lifecore Biomedical, Inc. will report its financial results for the second quarter of fiscal year 2025 on January 2, 2025, after market close [1] - A webcast will be hosted by Lifecore's senior management team at 4:30 p.m. Eastern Time on the same day to discuss the financial results and recent corporate developments [1] Company Overview - Lifecore Biomedical is a fully integrated contract development and manufacturing organization (CDMO) specializing in the development, fill, and finish of sterile injectable pharmaceutical products, including complex formulations [3] - The company has over 40 years of expertise in manufacturing premium, injectable-grade hyaluronic acid and partners with global and emerging biopharmaceutical and biotechnology companies across multiple therapeutic categories [3]

Core Insights - Lifecore Biomedical has been selected by Nirsum Laboratories to provide contract development and manufacturing organization (CDMO) services for the clinical development of NRS-033, a treatment for opioid use disorder (OUD) and alcohol use disorder (AUD) [1][2][5] - The agreement includes technology transfer and assessment of the fill and finish process for NRS-033, leveraging Lifecore's expertise in sterile injectable pharmaceutical products [1][3] - NRS-033 aims to address the high relapse rates associated with current therapies for OUD and AUD, with the potential to improve therapeutic retention for patients [3][5] Company Overview - Lifecore Biomedical is a fully integrated CDMO specializing in the development, fill, and finish of sterile injectable pharmaceutical products, including complex formulations [4] - The company has over 40 years of experience and serves global and emerging biopharmaceutical and biotechnology companies [4] - Nirsum Laboratories is a development-stage biotechnology company focused on creating curable treatments for addiction, with NRS-033 being funded in part by the NIH [5]